Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Total Non-Current Liabilities (2020 - 2025)

Historic Total Non-Current Liabilities for SAB Biotherapeutics (SABSW) over the last 6 years, with Q3 2025 value amounting to $16.0 million.

  • SAB Biotherapeutics' Total Non-Current Liabilities rose 2482.61% to $16.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.0 million, marking a year-over-year increase of 2482.61%. This contributed to the annual value of $11.8 million for FY2024, which is 2038.6% down from last year.
  • SAB Biotherapeutics' Total Non-Current Liabilities amounted to $16.0 million in Q3 2025, which was up 2482.61% from $16.1 million recorded in Q2 2025.
  • SAB Biotherapeutics' Total Non-Current Liabilities' 5-year high stood at $31.9 million during Q4 2021, with a 5-year trough of $4.3 million in Q1 2021.
  • For the 5-year period, SAB Biotherapeutics' Total Non-Current Liabilities averaged around $15.2 million, with its median value being $15.1 million (2023).
  • Per our database at Business Quant, SAB Biotherapeutics' Total Non-Current Liabilities surged by 46640.87% in 2022 and then plummeted by 4117.32% in 2023.
  • Quarter analysis of 5 years shows SAB Biotherapeutics' Total Non-Current Liabilities stood at $31.9 million in 2021, then crashed by 38.73% to $19.5 million in 2022, then decreased by 23.86% to $14.9 million in 2023, then decreased by 20.39% to $11.8 million in 2024, then skyrocketed by 35.11% to $16.0 million in 2025.
  • Its last three reported values are $16.0 million in Q3 2025, $16.1 million for Q2 2025, and $15.4 million during Q1 2025.